Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 4/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13118870 | 0.92 | GSK3B (0.67) | GSK3BCDK2CCNE1 | |
| SCHEMBL13289050 | 0.88 | GSK3B (0.58) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13305370 | 0.85 | GSK3B (0.61) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13288625 | 0.85 | GSK3B (0.56) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13288837 | 0.85 | GSK3B (0.57) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13289048 | 0.85 | GSK3B (0.59) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13119113 | 0.84 | GSK3B (0.64) | GSK3BCDK2CCNE1 | |
| SCHEMBL13288814 | 0.84 | GSK3B (0.61) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL12953848 | 0.84 | GSK3B (0.61) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13288752 | 0.83 | GSK3B (0.55) | GSK3BCHEK1CDK2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |